Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Sees Significant Growth in Short Interest

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPFGet Free Report) was the target of a significant growth in short interest during the month of May. As of May 29th, there was short interest totaling 33,275 shares, a growth of 114.3% from the May 14th total of 15,525 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Towa Pharmaceutical to an “overweight” rating in a research report on Friday. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Towa Pharmaceutical currently has a consensus rating of “Buy”.

View Our Latest Analysis on TWAPF

Towa Pharmaceutical Stock Performance

Shares of OTCMKTS:TWAPF opened at $25.33 on Friday. The firm’s 50 day moving average is $25.33 and its two-hundred day moving average is $25.33. Towa Pharmaceutical has a 52 week low of $16.83 and a 52 week high of $25.33.

Towa Pharmaceutical Company Profile

(Get Free Report)

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.

See Also

Receive News & Ratings for Towa Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Towa Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.